Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 45 Products per page

Ximency
Read More
Ximency (Bristol-Myers Squibb) is a twice-daily fixed-dose combination of daclatasvir, a first-generation NS5A inhibitor; asunaprevir, an NS3 protease inhibitor; and beclabuvir, a non-nucleoside NS5B inhibitor. The combination is approved in Japan for the treatment of genotype 1 (GT-1) chronic hepatitis C virus infection.
November 6, 2017
Find out more
Mavenclad
Read More
Mavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms.
November 24, 2017
Find out more
Bavencio
Read More
Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.
March 6, 2019
Find out more
2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…
October 18, 2019
Find out more
Evinacumab
Read More
Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase.
November 20, 2018
Find out more
Mirvetuximab Soravtansine
Read More
Mirvetuximab soravtansine (ImmunoGen) is a folate receptor alpha (FRa)-targeted antibody-drug conjugate (ADC) in development for advanced ovarian cancer patients that overexpress FRa. It is comprised of an FRa-targeted monoclonal antibody linked to the cytotoxic effector compound maytansinoid DM4.
August 17, 2017
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
U.S. Markets for Compression Therapy and Pressure Reduction and Relief Products Used for Wound Management

$3,750.00

The scope of this report includes compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression devices) and pressure reduction and relief products (e.g., specialty/integrated beds, mattress replacements, and mattress overlays).

April 1, 2013
Find out more
Ivosidenib
Read More
Ivosidenib is an oral selective reversible inhibitor of the mutant form of the IDH1 enzyme that is associated with a wide range of cancers, including approximately 6–9% of AML cases.
July 6, 2017
Find out more
Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

$4,750.00

In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
July 1, 2020
Find out more
Teflaro
Read More
Teflaro (ceftaroline fosamil; Actavis/AstraZeneca/Dainippon Sumitomo Pharma) is a fifth-generation cephalosporin.
September 29, 2016
Find out more
Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing
May 7, 2014
Find out more
Lovenox
Read More
Lovenox (enoxaparin; Sanofi/Kaken Pharmaceutical) is a subcutaneous low molecular weight heparin approved for the prophylaxis of deep vein thrombosis (DVT)…
August 2, 2016
Find out more
Prolia
Read More
Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis.
March 9, 2018
Find out more
Entrectinib
Read More
Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
August 30, 2018
Find out more
Company Analysis: Eli Lilly

$3,000.00

PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Pyridorin
Read More
Pyridorin’s (pyridoxamine; NephroGenex) trial program has been put on hold due to company finances

and lack of investor/partner interest, so could well be suspended.
April 15, 2016
Find out more
TAK-003
Read More
TAK-003 (Takeda) is a needle-free, tetravalent live-attenuated vaccine currently in Phase II/III development in the US and dengue-endemic countries in Asia and Latin America, including Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Peru, the Philippines, Sri Lanka, Thailand, and Vietnam.
January 4, 2018
Find out more
2015 Jardiance EMPA-REG CVOT Pulse

$599.00

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).
November 1, 2015
Find out more
Disease Analysis: Psoriasis
Read More
First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.
March 21, 2022
Find out more
Cosentyx
Read More
Cosentyx (secukinumab; Novartis) is a fully human monoclonal antibody which acts by neutralizing interleukin (IL)-17A. IL-17A is a pro-inflammatory cytokine secreted by activated T cells. It is indicated for the treatment of plaque psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis.
May 16, 2018
Find out more
Tagrisso
Read More
Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca.
August 30, 2016
Find out more
The Real Value of Medtech Markets: The impact of currency movements

$2,995.00

This report provides a comprehensive picture of the global medical orthopaedics market and relevant background, using the latest data and expert analysis. The report covers the top 160 markets by estimated US dollar value in 2019.
November 27, 2019
Find out more
U.S. Markets for Heart Valve Disorder Management Products

$4,750.00

This comprehensive report examines the etiology and epidemiology, number of hospital discharges, incidence and prevalence, and mortality rates of the most prevalent diseases/disorders in the United States for the years 2000-2010, and 2013.
September 22, 2016
Find out more
ALKS 3831
Read More
ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.
April 9, 2018
Find out more
Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

$2,995.00

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.
October 17, 2016
Find out more
Market Spotlight: Chemotherapy-Induced Anemia

$1,318.00

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Disease Analysis: Asthma
Read More
Since its launch as the first fixed-dose combination (FDC) of an inhaled corticosteroid (ICS) and a long-acting beta 2 agonist (LABA), GlaxoSmithKline’s Advair has become a well-established gold-standard therapy in asthma. However, generic competition in Europe, and more recently in the US, marks the end of this successful history.
March 21, 2022
Find out more
Lemtrada
Read More
Lemtrada contains the monoclonal antibody alemtuzumab, which specifically targets cluster of differentiation (CD)52 expressed on the surface of normal and malignant T cells, thus depleting the T lymphocytes involved in the degradation of the myelin sheath.
November 24, 2017
Find out more
Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

$599.00

This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.
January 18, 2019
Find out more
Etrolizumab
Read More
Etrolizumab (Roche) is a humanized anti-beta 7 integrin subunit monoclonal antibody in Phase III development for the treatment of ulcerative colitis.
August 2, 2018
Find out more
Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
Find out more
Market Spotlight: Huntington’s Disease

$1,318.00

This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
May 5, 2022
Find out more
Zepatier
Read More
Zepatier is a once-daily, fixed-dose combination of Merck & Co’s second-generation protease inhibitor, grazoprevir, and the company’s NS5A inhibitor, elbasvir.
November 6, 2017
Find out more
Dalvance
Read More
Dalvance is a second-generation, semi-synthetic lipoglycopeptide antibacterial compound of the same class as vancomycin. The drug inhibits the formation of, and disrupts the integrity of…
September 10, 2014
Find out more
Remodulin
Read More
Remodulin (treprostinil; United Therapeutics/Antigen/Mochida) is a prostaglandin analog that functions as a prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Company Analysis: UCB

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
January 25, 2021
Find out more
U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

$3,750.00

The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.
July 1, 2013
Find out more
Keytruda
Read More
Keytruda is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells.
February 26, 2020
Find out more
Vasotec
Read More
Vasotec’s (enalapril; Merck & Co/Valeant) role in chronic heart failure (CHF) is severely limited by

competition from generic equivalents.
August 2, 2016
Find out more
Orthobiologics Market for Musculoskeletal Soft Tissue Replacement and Regeneration

$4,750.00

This report provides an analysis and sales forecast for the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. Market segments covered in this report include:
July 20, 2017
Find out more
Letairis
Read More
Letairis (ambrisentan; Gilead/AbbVie/GlaxoSmithKline) is a selective endothelin type A (ETA) receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory.
October 29, 2018
Find out more
2015 PCSK9 Inhibitors Pulse

$599.00

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.
August 19, 2015
Find out more
Market Spotlight: Glioblastoma (GBM)

$1,318.00

This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
April 14, 2022
Find out more
Lenvima
Read More
Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).
September 9, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *